Immunological Effects of a Tumor Necrosis Factor Alpha-Armed Oncolytic Adenovirus

Human Gene Therapy

Volumn 26, Issue 3, 2015, Pages 134-144

  Hirvinen, Mari ^a,b   Rajecki, Maria ^b   Kapanen, Mika ^c   Parviainen, Suvi ^b   Rouvinen Lagerström, Noora ^b   Diaconu, Iulia ^b   Nokisalmi, Petri ^b   Tenhunen, Mikko ^c   Hemminki, Akseli ^b,d,e   Cerullo, Vincenzo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TILT Biotherapeutics   (Finland)

^e Docrates Oncology Clinic   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS; OVALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENCY; EMBRYO; GENE; GENE PRODUCT; HTNFALPHA GENE; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSGENE; TUMOR CELL; TUMOR IMMUNITY; ADENOVIRIDAE; GENE THERAPY; GENE VECTOR; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; NEOPLASMS; NONPARAMETRIC TEST; ONCOLYTIC VIROTHERAPY; PROCEDURES; THERAPEUTIC USE; TUMOR CELL LINE;

ADENOVIRIDAE;

ADENOVIRIDAE; APOPTOSIS; CELL LINE, TUMOR; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924965590     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.069     Document Type: Article

References (49)

1. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010;18:243-250.
2. Prestwich RJ, et al. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008;8:1581-1588.
3. Tong AW, et al. Oncolytic viruses for induction, of anti-tumor immunity. Curr Pharm Biotechnol 2011;13:1750-1760.
4. Hallden G, Portella G. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin Ther Targets 2012;16:945-958.
5. Diaconu I, et al. Immune response is an important aspect of the anti-tumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 2012;72:2327-2338.
6. Koski A, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010;18:1874-1884.
7. Carswell EA, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-3670.
8. Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-632.
9. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-371.
10. Mueller H. Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci 1998;54:1291-1298.
11. Schiller JH, et al. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res 1991;51:1651-1658.
12. Lienard D, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
13. Eggermont AM, De Wilt JH, Ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429-437.
14. Van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006;11:397-408.
15. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199-212.
16. Hallahan DE, Beckett MA, Kufe D, et al. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys 1990;19:69-74.
17. Mauceri HJ, et al. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther 2009;16:373-381.
18. Weichselbaum RR, Kufe D. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther 2009;16:609-619.
19. Fisher WE. The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark. World J Surg 2011;35:1766-1769.
20. Kanerva A, et al. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther 2005;12:87-94.
21. Kanerva A, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003;8:449-458.
22. Kanerva A, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002;8:275-280.
23. Kepp O, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011;30:61-69.
24. Liikanen I, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013;21:1212-1223.
25. Mocellin S, Rossi CR, Pilati P, et al. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005;16:35-53.
26. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-1308.
27. Salako MA, et al. Inhibition of the inflammatory cytokine TNF-alpha increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Mol Ther 2011;19:490-499.
28. Seki T, et al. Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. J Control Release 2011;156:381-389.
29. Mcloughlin JM, et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol 2005;12:825-830.
30. Corti A. Strategies for improving the anti-neoplastic activity of TNF by tumor targeting. Methods Mol Med 2004;98:247-264.
31. Kobelt D, et al. Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector. Mol Oncol 2014;8:609-619.
32. Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol 1999;19:350-364.
33. Parviainen S, et al. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Ther 2014;21:195-204.
34. Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther 2014;22:251-256.
35. Cerullo V, et al. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther 2012;20:2076-2086.
36. Helmy KY, Patel SA, Nahas GR, et al. Cancer immunotherapy: accomplishments to date and future promise. Ther Deliv 2013;4:1307-1320.
37. Sobol PT, et al. Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther 2011;19:335-344.
38. Miller CG, Fraser NW. Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol Ther 2003;7:741-747.
39. Nakamori M, et al. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 2004;9:658-665.
40. Cauwels A, Fiers W, Brouckaert P. Murine IL-12 is involved in Calmette-Guerin bacillus-induced sensitization and is by itself sufficient to sensitize mice to the lethal effects of human TNF1. J Immunol 1996;156:4686-4690.
41. Han ZQ, et al. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med 2007;9:99-106.
42. Asher A, et al. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-974.
43. Talmadge JE, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988;48:544-550.
44. Fransen L, Ruysschaert MR, Van Der Heyden J, et al. Recombinant tumor necrosis factor: species specificity for a variety of human and murine transformed cell lines. Cell Immunol 1986;100:260-267.
45. Calzascia T, et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007;117:3833-3845.
46. Chung TD, et al. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther 1998;5:344-349.
47. Hallahan DE, et al. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am 1995;1:204-209.
48. Touchefeu Y, Vassaux G, Harrington KJ. Oncolytic viruses in radiation oncology. Radiother Oncol 2011;99:262-270.
49. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985;11:1699-1707.